![Zi Qiang Cheng](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Zi Qiang Cheng
Società | Posizione | Inizio | Fine |
---|---|---|---|
Zion Pharma Ltd.
![]() Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Amministratore Delegato | 01/01/2018 | - |
Presidente | 01/01/2018 | - | |
Fondatore | 01/01/2018 | - |
Storia della carriera di Zi Qiang Cheng
Statistiche
Distribuzione geografica
Cina | 2 |
Posizioni
Chief Executive Officer | 1 |
Chairman | 1 |
Founder | 1 |
Settori
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Zion Pharma Ltd.
![]() Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Commercial Services |
- Borsa valori
- Insiders
- Zi Qiang Cheng
- Esperienza